Wedbush Trims Sutro Biopharma (NASDAQ:STRO) Target Price to $8.00

Sutro Biopharma (NASDAQ:STRO) had its target price trimmed by Wedbush from $12.00 to $8.00 in a report published on Tuesday morning, MarketBeat Ratings reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for Sutro Biopharma’s Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.76) EPS.

Several other brokerages have also recently weighed in on STRO. JMP Securities reaffirmed a market outperform rating and issued a $17.00 price target on shares of Sutro Biopharma in a research report on Tuesday. HC Wainwright dropped their price objective on shares of Sutro Biopharma from $16.00 to $12.00 and set a buy rating on the stock in a report on Tuesday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of Buy and an average target price of $13.71.

Sutro Biopharma Price Performance

Shares of Sutro Biopharma stock opened at $4.93 on Tuesday. Sutro Biopharma has a one year low of $2.01 and a one year high of $6.11. The stock’s 50-day moving average is $4.47 and its 200 day moving average is $3.77. The firm has a market cap of $300.48 million, a price-to-earnings ratio of -2.77 and a beta of 0.95.

Insiders Place Their Bets

In other news, insider Nicki Vasquez sold 12,185 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $5.00, for a total value of $60,925.00. Following the completion of the sale, the insider now owns 12,803 shares of the company’s stock, valued at approximately $64,015. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of STRO. American Century Companies Inc. grew its holdings in shares of Sutro Biopharma by 14.3% during the 1st quarter. American Century Companies Inc. now owns 14,656 shares of the company’s stock worth $66,000 after acquiring an additional 1,833 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Sutro Biopharma by 9.9% in the 4th quarter. The Manufacturers Life Insurance Company now owns 20,667 shares of the company’s stock worth $167,000 after purchasing an additional 1,864 shares during the period. Principal Financial Group Inc. raised its position in shares of Sutro Biopharma by 13.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,348 shares of the company’s stock valued at $71,000 after purchasing an additional 1,874 shares during the period. American International Group Inc. raised its position in shares of Sutro Biopharma by 9.8% during the 4th quarter. American International Group Inc. now owns 25,500 shares of the company’s stock valued at $206,000 after buying an additional 2,273 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Sutro Biopharma by 24.2% in the first quarter. Prudential Financial Inc. now owns 14,390 shares of the company’s stock valued at $66,000 after acquiring an additional 2,800 shares during the period. 96.99% of the stock is owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.